时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Berberine (BBR), a component of the Chinese herb, is used for treating diabetes and diabetes-associated cognitive dysfunction (DACD), although the underlying mechanism is still unclear. Diabetes is a metabolic disease that raises the risk of developing cognitive impairment. The hippocampus within the forebrain has large number of insulin receptors linked to cognitive function and is crucial in the pathophysiology of neurodegenerative disorders. Herein, we examined whether BBR could improve DACD and explored the possible underlying mechanisms.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★☆☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
原文题录
- 英文标题：Berberine improves cognitive impairment in diabetic mice by mitigating 4-HNE-induced oxidative stress and enhancing hippocampal insulin sensitivity.
- 期刊与标识：Mol Biol Rep · PMID 42961528 · DOI 10.1007/s11033-026-13042-9
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。